Search for Clinical Trial Results
Choroidal Neovascularization - 25 Studies Found
Status | Study |
Withdrawn |
Study Name: Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID). Condition: Choroidal Neovascularization in Angioid Streaks Date: 2015-10-07 Interventions: Drug: Aflibercept The patients are followed on a monthly basis until 52 weeks. Intravitreal injections o |
Completed |
Study Name: Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. Condition: Choroidal Neovascularization (CNV) Date: 2013-04-23 Interventions:
|
Completed |
Study Name: Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization Condition: Subfoveal Choroidal Neovascularization Date: 2006-12-01 Interventions:
|
Completed |
Study Name: Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Condition: Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Date: 2013-08-12 Interventions:
|
Completed |
Study Name: Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration. Condition: Choroidal Neovascularization Date: 2006-11-01 Interventions: Drug: ranibizumab 0.5mg intravitreal injection |
Completed |
Study Name: Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks Condition:
Date: 2006-06-30 Interventions: Drug: Intravitreal Bevacizumab |
Completed |
Study Name: Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia Condition:
Date: 2011-08-22 Interventions: Drug: Combretastatin A-4 Phosphate Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- |
Recruiting |
Study Name: AVENUE: A Proof-of-Concept Study of RG7716 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Condition: Macular Degeneration, Choroidal Neovascularization Date: 2015-06-12 Interventions:
|
Completed |
Study Name: Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Condition:
Date: 2007-02-16 Interventions:
|
Completed |
Study Name: A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. Condition: Choroidal Neovascularization Secondary to Pathologic Myopia Date: 2014-01-09 Interventions: Drug: Ranibizumab All patients will receive a single initial intravitreal injection of ranibizumab 0.5 m |